β-defensin 28 Inhibitors
β-Defensin 28 is a member of the defensin family, known for its antimicrobial properties and its role in innate immunity. It is predominantly expressed in epithelial cells, serving as a crucial component of the host defense system by providing protection against a broad spectrum of microorganisms.
The inhibition of β-defensin 28 can be achieved through various mechanisms involving key cellular pathways. The chemicals listed in the table exert their inhibitory effects by targeting specific pathways such as DNA repair (PARP inhibition), PI3K/AKT signaling, JAK-STAT pathway, calcineurin/NFAT, MAPK/ERK, JNK/AP-1, HDAC/chromatin remodeling, Wnt/β-catenin, hypoxia/HIF-1α, TLR4, and mTORC1. These inhibitors disrupt the signaling cascades involved in the transcriptional regulation of β-defensin 28, providing potential avenues for controlling its expression in different physiological contexts. The intricate interplay of these pathways highlights the complexity of β-defensin 28 regulation and presents diverse opportunities for targeted intervention in the context of innate immune responses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $178.00 $270.00 $712.00 | 3 | |
PARP inhibitor disrupting DNA repair. Veliparib indirectly inhibits β-defensin 28, as PARP inhibition affects the DNA damage response pathway, impacting the regulation of β-defensin 28 transcription under conditions of cellular stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. LY294002 indirectly hampers β-defensin 28, as PI3K/AKT signaling is implicated in the regulation of β-defensin 28 transcription by modulating the activity of specific transcription factors. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK inhibitor targeting JAK-STAT signaling. Ruxolitinib indirectly suppresses β-defensin 28, as the JAK-STAT pathway regulates the transcription of β-defensin 28 by activating STAT proteins. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
Calcineurin inhibitor affecting the NFAT pathway. Tacrolimus indirectly inhibits β-defensin 28 by blocking NFAT activation, a key regulator of β-defensin 28 transcription in response to various stimuli. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
MEK inhibitor influencing the MAPK/ERK pathway. Selumetinib indirectly influences β-defensin 28 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 28 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 28, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 28. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor modulating chromatin structure. Trichostatin A indirectly suppresses β-defensin 28 by altering histone acetylation, influencing the accessibility of the β-defensin 28 gene for transcription. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $163.00 | 4 | |
HIF-1α inhibitor affecting the hypoxia pathway. Echinomycin indirectly suppresses β-defensin 28, as HIF-1α enhances β-defensin 28 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $360.00 | ||
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 28, as TLR4 activation is known to upregulate β-defensin 28 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 28 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 28 through control of translation initiation. | ||||||